COMIRNATY® (BNT162b2) | mRNA-based vaccine | 95% | Pfizer, BioNTech; Fosun Pharma | Multinational | Albania, Argentina, Australia, Bahrain, Canada, Chile, Colombia, Costa Rica, Ecuador, EU, Faroe Islands, Greenland, Iceland, Iraq, Israel, Jordan, Kuwait, Malaysia, Mexico, Norway, Oman, Panama, Philippines, Qatar, Saudi Arabia, Serbia, Singapore, Switzerland, Tunisia, UAE, U.K, U.S |
AstraZeneca (AZD1222) | Adenovirus vaccine | 70% | AstraZeneca/Oxford University | UK | Argentina, Bahrain, Bangladesh, Brazil, Canada, Chile, Dominican Republic, Ecuador, El Salvador, EU, Hungary, India, Iraq, Mexico, Morocco, Myanmar, Nepal, Pakistan, Philippines, Saudi Arabia, South Africa, Sri Lanka, Thailand, Tunisia, UK, Vietnam |
Sputnik V | Viral Vector | 92% | Russia’s Gamaleya Institute | Russie | Algeria, Argentina, Armenia, Belarus, Bolivia, Guinea, Hungary, Iran, Mexico, Pakistan, Palestine, Paraguay, Russia, Serbia, Tunisia, Turkmenistan, United Arab Emirates, Venezuela |
CoronaVac | Inactivated vaccine | 51% | Chinese vaccine developer Sinovac | china | |